TCRT-PGEN Fundamental & Technical Discussion Board - MRNA stock surges on cancer vaccine development pact with MRK - TCRT-PGEN Fundamental & Technical Discussion Board - InvestorVillage


TCRT-PGEN Fundamental & Technical Discussion Board
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: TCRT-PGEN Fundamental & Technical Discussion Board   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  30902 of 32313  at  10/12/2022 9:22:15 AM  by

Bronxboy50


MRNA stock surges on cancer vaccine development pact with MRK

 

Moderna Stock Surges On Cancer Vaccine Development Pact With Merck

"Together we have made significant progress in advancing mRNA-4157 as an investigational personalized cancer treatment used in combination with (Merck & Co.'s) Keytruda," Moderna said Wednesday.

Moderna (MRNA) shares surged higher Wednesday after the drugmaker said it will work with Merck & Co (MRK) to develop and market an mRNA structed cancer vaccine.

Moderna said it will exercise and earlier option with Merck to allow the collaboration of its new messenger RNA-based vaccine, known as mRNA-4157, to be developed alongside Merck's blockbuster Keytruda treatment. Merck will pay Moderna $250 million as part of the option agreement.

Personalized cancer vaccines, the companies said, are designed to prime the immune system so that a patient can generate a tailored antitumor response to their tumor mutation signature to treat their cancer. The new vaccine, Moderna said, is undergoing mid-stage trials with data expected before the end of the year.

"We have been collaborating with Merck on PCVs since 2016, and together we have made significant progress in advancing mRNA-4157 as an investigational personalized cancer treatment used in combination with Keytruda," said Moderna president Stephen Hoge.

"With data expected this quarter on PCV, we continue to be excited about the future and the impact mRNA can have as a new treatment paradigm in the management of cancer. Continuing our strategic alliance with Merck is an important milestone as we continue to grow our mRNA platform with promising clinical programs in multiple therapeutic areas."

Moderna shares were marked 8.5% higher in pre-market trading following news of the collaboration with Merck to indicate an opening bell price of $130.80 each. Merck shares, meanwhile, edged 0.3% higher to $91.31 each.

Earlier this year, Moderna re-affirmed its full-year forecast for Covid vaccine sales, forecasting overall revenues of around $21 billion, with orders weighted slightly into the second half of the year.

The group also said it would sue Pfizer (PFE) , as well as its German partner BioNTech (BNTX) , for allegedly copying its messenger-RNA technologies.

Moderna said it will seek unspecified relief in both a U.S. and German court after altering its pledge not to enforce patents related to its mRNA-1273 coronavirus vaccine, known as Spikevax in wealthy countries.

The drugmaker said it had expected Pfizer and Moderna to consider a "commercially reasonable" licensing agreement as a result, but have to date "failed to do so".



     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
30909 Re: MRNA stock surges on cancer vaccine development pact with MRK Eatsmelts 3 10/12/2022 10:21:18 AM
30932 Re: MRNA stock surges on cancer vaccine development pact with MRK Eatsmelts 6 10/13/2022 12:05:50 PM




Financial Market Data provided by
.
Loading...